Systematic Reviews/Meta-Analysis
Tuesday, October 15, 2024
08:30 AM–10:00 AM
Abstract
Background:
Ceftriaxone, a third-generation cephalosporin, treats various bacterial infections. Dosing ranges from 1-2 grams intravenously (IV) daily for non-central nervous system (CNS) infections depending on indication and severity. This meta-analysis compared the efficacy of ceftriaxone 1 gram IV daily to higher dosing regimens for the treatment of non-CNS infections in adults.
Methods: Literature was queried from PubMed, Embase, Scopus, and Web of Science database inception to August 8, 2023. Randomized controlled trials and observational studies reporting clinical cure (CC), length of hospital stay (LOS), mortality, and/or toxicity requiring therapy alteration were included. First abstracts were screened for relevance and selected abstracts were independently reviewed for inclusion by at least two authors; a third adjudicated disagreements. The risk of bias was assessed using ROB-2 and ROBBINS-I scores. CC was evaluated using a Mantel-Haenszel random-effects model with Peto odds ratios (pORs) and 95% confidence intervals (CIs) reported. Heterogeneity was measured using 2 statistic. Publication bias was assessed by visual inspection of a funnel plot of the studies and Egger’s regression. Comprehensive Meta-Analysis 3.0 was used for analyses.
Results: Seven(N=5020) met inclusion criteria; 4 were analyzed for CC (n=725); 5 for LOS (n=4769); 4 for mortality (n=4675); and 5 for toxicity (n=4576). No statistically significant difference was found between 1 versus 2 grams IV daily for CC [pOR 1.113, 95% CI (0.681-1.817); p=0.669, I2Presenting AuthorJessica Hu PharmD, BCCCPAuthors
Matthew Bridgeman MLIS
Rutgers, The State University of New Jersey
Luigi Brunetti PharmD, PhD
Lindsay Brust-Sisti PharmD, BCPS
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey
Jimmy Gonzalez PharmD, MPH
Rutgers University